Previous 10 | Next 10 |
2024-04-03 11:37:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics gains as late-stage trial for lead drug succeeds...
2024-03-19 16:14:34 ET More on Crinetics Pharmaceuticals Crinetics gains as late-stage trial for lead drug succeeds Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Read ...
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is one of today's top gainers. The company's shares have moved 15.53% on the day to $43.82. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for ...
2024-03-19 07:04:13 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics reports encouraging Phase 2 data for carcinoid s...
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a...
2024-03-12 17:04:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Citi starts Crinetics at buy, cites upcoming data for lead...
Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Prev...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its co...
2024-03-06 11:53:55 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Crinetics Pharmaceu...
2024-02-29 09:15:03 ET Cantor Fitzgerald analyst issues UNDERPERFORM recommendation for CRNX on February 29, 2024 08:01AM ET. The previous analyst recommendation was Underperform. CRNX was trading at $42.76 at issue of the analyst recommendation. The overall analyst cons...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...